{"id":"ocriplasmin","rwe":[{"pmid":"41588777","year":"2026","title":"Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors.","finding":"","journal":"Biotechnology and applied biochemistry","studyType":"Clinical Study"},{"pmid":"41456064","year":"2025","title":"Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.","finding":"","journal":"Discover oncology","studyType":"Clinical Study"},{"pmid":"41073807","year":"2025","title":"Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System.","finding":"","journal":"Eye (London, England)","studyType":"Clinical Study"},{"pmid":"40504290","year":"2025","title":"Risk factors and efficacy of different intravitreal treatment options for symptomatic focal vitreomacular traction with or without full-thickness macular hole.","finding":"","journal":"International ophthalmology","studyType":"Clinical Study"},{"pmid":"39464178","year":"2024","title":"A Causal Inference Approach to Mediation Analysis in Vitreomacular Traction: How Much Does Traction Resolution Mediate Functional Outcomes?","finding":"","journal":"Journal of market access & health policy","studyType":"Clinical Study"}],"tags":[{"label":"Proteolytic Enzyme","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"S01XA22","category":"atc"},{"label":"Active","category":"status"},{"label":"Vitreomacular traction syndrome","category":"indication"},{"label":"Thrombogenics, Inc","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":543.994,"date":"","count":86,"signal":"Photopsia","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=544)"},{"llr":449.832,"date":"","count":96,"signal":"Visual acuity reduced","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=450)"},{"llr":433.238,"date":"","count":51,"signal":"Retinal injury","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=433)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Thrombogenics, Inc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OCRIPLASMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:28.754336+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:35.269671+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:21:28.827208+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCRIPLASMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:35.602044+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Collagen hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:36.663328+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2095222/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:36.302607+00:00"}},"allNames":"jetrea","offLabel":[],"synonyms":["ocriplasmin","microplasmin","ocriplasmine","jetrea","ocriplasmin (genetical recombination)"],"timeline":[{"date":"2012-10-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Thrombogenics, Inc)"},{"date":"2013-03-13","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"brandName":"Jetrea","ecosystem":[{"indication":"Vitreomacular traction syndrome","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Proteolytic Enzyme","explanation":"","oneSentence":"","technicalDetail":"Jetrea (ocriplasmin) is a recombinant form of human plasmin, a proteolytic enzyme that breaks down fibrin and other proteins. It works by activating plasminogen to plasmin, which then degrades the vitreomacular adhesion proteins, allowing the vitreous gel to separate from the retina."},"commercial":{"launchDate":"2012","_launchSource":"DrugCentral (FDA 2012-10-17, THROMBOGENICS, INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5004","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OCRIPLASMIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCRIPLASMIN","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:46:12.771013","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:37.946583+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"retinol","drugSlug":"retinol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"sodium chloride","drugSlug":"sodium-chloride","fdaApproval":"1965-12-16","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"potassium iodide","drugSlug":"potassium-iodide","fdaApproval":"1979-11-09","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetylcysteine","drugSlug":"acetylcysteine","fdaApproval":"1963-09-14","patentExpiry":"May 8, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inosine","drugSlug":"inosine","fdaApproval":"","relationship":"same-class"},{"drugName":"dexpanthenol","drugSlug":"dexpanthenol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"alteplase","drugSlug":"alteplase","fdaApproval":"1996-06-18","relationship":"same-class"},{"drugName":"heparin","drugSlug":"heparin","fdaApproval":"1939-02-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ascorbic acid","drugSlug":"ascorbic-acid","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclosporin","drugSlug":"ciclosporin","fdaApproval":"1983-11-14","relationship":"same-class"},{"drugName":"mercaptamine","drugSlug":"mercaptamine","fdaApproval":"1994-08-15","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lifitegrast","drugSlug":"lifitegrast","fdaApproval":"2016-07-11","patentExpiry":"Oct 21, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"riboflavin","drugSlug":"riboflavin","fdaApproval":"1953-02-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"varenicline","drugSlug":"varenicline","fdaApproval":"2006-05-10","patentExpiry":"Oct 19, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ocriplasmin","indications":{"approved":[{"name":"Vitreomacular traction syndrome","source":"DrugCentral","snomedId":312901001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"retinol","brandName":"retinol","genericName":"retinol","approvalYear":"1953","relationship":"same-class"},{"drugId":"sodium-chloride","brandName":"sodium chloride","genericName":"sodium chloride","approvalYear":"1965","relationship":"same-class"},{"drugId":"potassium-iodide","brandName":"potassium iodide","genericName":"potassium iodide","approvalYear":"1979","relationship":"same-class"},{"drugId":"acetylcysteine","brandName":"acetylcysteine","genericName":"acetylcysteine","approvalYear":"1963","relationship":"same-class"},{"drugId":"inosine","brandName":"inosine","genericName":"inosine","approvalYear":"","relationship":"same-class"},{"drugId":"dexpanthenol","brandName":"dexpanthenol","genericName":"dexpanthenol","approvalYear":"1953","relationship":"same-class"},{"drugId":"alteplase","brandName":"alteplase","genericName":"alteplase","approvalYear":"1996","relationship":"same-class"},{"drugId":"heparin","brandName":"heparin","genericName":"heparin","approvalYear":"1939","relationship":"same-class"},{"drugId":"ascorbic-acid","brandName":"ascorbic acid","genericName":"ascorbic acid","approvalYear":"","relationship":"same-class"},{"drugId":"ciclosporin","brandName":"ciclosporin","genericName":"ciclosporin","approvalYear":"1983","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02290795","phase":"","title":"Vitreopapillary Interface and Optic Disc Morphology","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-11","conditions":["Posterior Vitreous Detachment","Vitreomacular Traction","Glaucoma","Vitreopapillary Traction"],"enrollment":350,"completionDate":"2025-08"},{"nctId":"NCT04300881","phase":"PHASE2","title":"Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)","status":"TERMINATED","sponsor":"Wagner Macula & Retina Center","startDate":"2019-10-04","conditions":["Vitreomacular Traction","Subretinal Edema"],"enrollment":2,"completionDate":"2021-01-05"},{"nctId":"NCT02681809","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR","status":"TERMINATED","sponsor":"ThromboGenics","startDate":"2015-12","conditions":["Diabetic Retinopathy","Posterior Vitreous Detachment","Disease Progression"],"enrollment":48,"completionDate":"2019-11-18"},{"nctId":"NCT02322229","phase":"PHASE4","title":"Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-05-26","conditions":["Vitreomacular Traction","Vitreomacular Adhesion"],"enrollment":62,"completionDate":"2016-05-09"},{"nctId":"NCT01194674","phase":"PHASE1,PHASE2","title":"Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2011-01","conditions":["Uveitis"],"enrollment":2,"completionDate":"2011-12"},{"nctId":"NCT02747030","phase":"PHASE1","title":"Phase I RVC With Ocriplasmin for CRVO","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-12","conditions":["Central Retinal Vein Occlusion"],"enrollment":4,"completionDate":"2017-08-11"},{"nctId":"NCT01287988","phase":"","title":"Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2011-05","conditions":["Symptomatic Vitreomacular Adhesion"],"enrollment":24,"completionDate":"2011-10"},{"nctId":"NCT02035748","phase":"PHASE4","title":"Assessment of Patients Treated With JETREA® for Vitreomacular Traction","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-04","conditions":["Vitreomacular Traction","Vitreomacular Adhesion"],"enrollment":628,"completionDate":"2015-09"},{"nctId":"NCT02079883","phase":"","title":"Ocriplasmin Research to Better Inform Treatment (ORBIT)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2014-05","conditions":["Symptomatic Vitreomacular Adhesion"],"enrollment":540,"completionDate":"2016-05"},{"nctId":"NCT01429441","phase":"PHASE3","title":"Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2011-10","conditions":["Vitreomacular Adhesion Including Macular Hole"],"enrollment":220,"completionDate":"2014-10"},{"nctId":"NCT02001701","phase":"NA","title":"Intravitreal Gas for Vitreomacular Adhesion","status":"WITHDRAWN","sponsor":"Northern California Retina Vitreous Associates","startDate":"2013-11","conditions":["Vitreomacular Adhesion"],"enrollment":0,"completionDate":"2015-06"},{"nctId":"NCT01889251","phase":"PHASE3","title":"A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-07","conditions":["Symptomatic Vitreomacular Adhesion"],"enrollment":251,"completionDate":"2014-09"},{"nctId":"NCT02193945","phase":"","title":"A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2014-08","conditions":["Symptomatic Vitreomacular Adhesion (VMA)"],"enrollment":134,"completionDate":"2015-05"},{"nctId":"NCT00435539","phase":"PHASE2","title":"A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2007-02","conditions":["Vitreomacular Traction"],"enrollment":60,"completionDate":"2009-02"},{"nctId":"NCT00986362","phase":"PHASE2","title":"Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2010-02","conditions":["Vitrectomy"],"enrollment":24,"completionDate":"2012-04"},{"nctId":"NCT00798317","phase":"PHASE3","title":"Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2008-12","conditions":["Vitreomacular Adhesion"],"enrollment":326,"completionDate":"2010-07"},{"nctId":"NCT00412958","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2006-12","conditions":["Vitrectomy"],"enrollment":125,"completionDate":"2008-10"},{"nctId":"NCT00781859","phase":"PHASE3","title":"Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2008-12","conditions":["Vitreomacular Adhesion"],"enrollment":326,"completionDate":"2010-04"},{"nctId":"NCT00412451","phase":"PHASE2","title":"A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2006-12","conditions":["Diabetic Macular Edema"],"enrollment":51,"completionDate":"2010-03"},{"nctId":"NCT01159665","phase":"PHASE2","title":"The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2010-07","conditions":["Vitrectomy"],"enrollment":38,"completionDate":"2011-01"},{"nctId":"NCT00913744","phase":"PHASE2","title":"Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2010-01","conditions":["Exudative Age-Related Macular Degeneration","Focal Vitreomacular Adhesion"],"enrollment":100,"completionDate":"2013-04"},{"nctId":"NCT00123305","phase":"PHASE2","title":"Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2005-10","conditions":["Stroke, Acute"],"enrollment":40,"completionDate":"2008-06"},{"nctId":"NCT01055535","phase":"PHASE2","title":"Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2010-01","conditions":["Focal Vitreomacular Adhesion"],"enrollment":17,"completionDate":"2011-04"},{"nctId":"NCT00123292","phase":"PHASE2","title":"Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion","status":"TERMINATED","sponsor":"ThromboGenics","startDate":"2005-03","conditions":["Arterial Occlusive Diseases"],"enrollment":19,"completionDate":"2009-11"},{"nctId":"NCT00428129","phase":"PHASE2","title":"Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT","status":"TERMINATED","sponsor":"ThromboGenics","startDate":"2007-03","conditions":["Deep Vein Thrombosis"],"enrollment":6,"completionDate":"2008-10"},{"nctId":"NCT00123279","phase":"PHASE2","title":"Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2004-12","conditions":["Vitreomacular Traction Maculopathy","Eye Diseases"],"enrollment":60,"completionDate":"2008-11"},{"nctId":"NCT00123266","phase":"PHASE2","title":"Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion","status":"TERMINATED","sponsor":"ThromboGenics","startDate":"2006-12","conditions":["Stroke"],"enrollment":2,"completionDate":"2008-08"},{"nctId":"NCT00996684","phase":"PHASE2","title":"Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2009-10","conditions":["Macular Degeneration"],"enrollment":30,"completionDate":"2011-12"}],"_emaApprovals":[{"date":"2013-03-13","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000186140","MMSL":"194281","NDDF":"014688","UNII":"7V6HE3DM5A","VUID":"4032029","VANDF":"4032029","INN_ID":"9178","RXNORM":"1315214","UMLSCUI":"C0066522","chemblId":"CHEMBL2095222","ChEMBL_ID":"CHEMBL2095222","KEGG_DRUG":"D09646","DRUGBANK_ID":"DB08888","SNOMEDCT_US":"710290003","IUPHAR_LIGAND_ID":"7446","MESH_SUPPLEMENTAL_RECORD_UI":"C054561"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2012-","companyName":"Thrombogenics, Inc","relationship":"Original Developer"}],"publicationCount":277,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01XA22","allCodes":["S01XA22"]},"biosimilarFilings":[],"originalDeveloper":"Thrombogenics, Inc","recentPublications":[{"date":"2026 Jan 26","pmid":"41588777","title":"Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors.","journal":"Biotechnology and applied biochemistry"},{"date":"2025 Dec 27","pmid":"41456064","title":"Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.","journal":"Discover oncology"},{"date":"2025 Dec","pmid":"41073807","title":"Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System.","journal":"Eye (London, England)"},{"date":"2025 Jun 12","pmid":"40504290","title":"Risk factors and efficacy of different intravitreal treatment options for symptomatic focal vitreomacular traction with or without full-thickness macular hole.","journal":"International ophthalmology"},{"date":"2024 Dec","pmid":"39464178","title":"A Causal Inference Approach to Mediation Analysis in Vitreomacular Traction: How Much Does Traction Resolution Mediate Functional Outcomes?","journal":"Journal of market access & health policy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Thrombogenics, Inc","companyId":"thrombogenics-inc","modality":"Recombinant protein","firstApprovalDate":"2012","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:37.946583+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}